NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

June 07, 2022

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

May 17, 2022

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

May 17, 2022

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

April 18, 2022

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

April 14, 2022

Dr D’Abreo discusses adverse effects that are common in metastatic breast cancer, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.

April 13, 2022

Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.

March 21, 2022

Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.

February 04, 2022

Faith E. Davies, MD, a nationally renowned hematology expert, has been appointed the inaugural director of the Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.

January 31, 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.

January 31, 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the process of selecting applicants to be accepted into an oncology fellowship.

January 31, 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss whether it's still a possibility to be a general oncologist following an oncology fellowship.

January 31, 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the compact style that comprises oncology fellowship training.

January 31, 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share advice in selecting a mentor during an oncology fellowship.

January 28, 2022

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.

January 28, 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share their experiences as a fellowship director and an oncology fellow, respectively.

January 14, 2022

Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.

December 15, 2021

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.

December 02, 2021

Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer.

November 01, 2021

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

September 16, 2021

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.